immy_8a12b.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________
 
FORM 8-A
________________________
 
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
 
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934

IMPRIMIS PHARMACEUTICALS, INC
(Exact name of registrant as specified in its charter)

Delaware
 
45-0567010
(State of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
437 S. Hwy 101, Suite 209
Solana Beach, California
 
92075
(Address of principal executive offices)
 
(Zip Code)
 
Securities to be registered pursuant to Section 12(b) of the Act:
 
Title of each class
to be so registered
 
Name of each exchange on which
each class is to be registered
Common Stock,
$0.001 par value per share
 
The NASDAQ Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.  þ
 
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.  p
 
Securities Act registration statement file number to which this form relates:  File No. 333-182846
 
Securities to be registered pursuant to Section 12(g) of the Act:  None
 


 
 
 

 
 
Item 1.Description of Registrant’s Securities to be Registered.
 
Imprimis Pharmaceuticals, Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, par value $0.001 per share, to be registered hereunder that is contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-182846), as originally filed with the Securities and Exchange Commission (the “Commission”) on July 25, 2012 and as subsequently amended (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.
 
Item 2.Exhibits.
 
Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed herewith because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
 
 
2

 
 
SIGNATURE
 
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
  IMPRIMIS PHARMACEUTICALS, INC.  
       
Date:  February 7, 2013
By:
/s/ Andrew R. Boll   
  Name: Andrew R. Boll  
  Title:  Vice-President of Accounting and Public Reporting  
       
 

3